Navigation Links
OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
Date:9/30/2009

p>

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of OPAXIO include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with OPAXIO in particular, including, without limitation, the potential for OPAXIO to be proved safe and effective (or to achieve response rates) for the treatment of the indications noted in this press release or any other indication, determinations by regulatory, patent and administrative governmental authorities, the potential that OPAXIO will not produce high rates of complete remission in patients with advanced esophageal cancer, the possibility that the registration trial for OPAXIO as a radiation sensitizer will not occur, the possibility that the U.S. Food and Drug Administration will not approve a phase III registration strategy for paclitaxel poliglumex if proposed by CTI, the potential that Novartis will not exercise its option, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, and costs of developing, producing and selling OPAXIO. You should also review the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:

    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: deramian@ctiseattle.com
    www.CellT
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
2. Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis
3. OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
6. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
7. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
8. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
9. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
10. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
11. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... RADNOR, Pa. , Nov. 26, 2014 ... dedicated to the development of innovative transdermal synthetic cannabinoid ... the Piper Jaffray 26th Annual Healthcare Conference 2014. The ... the New York Palace in New York ... , will present at 4:50 pm on Tuesday, December ...
(Date:11/26/2014)... -- According to the new research ... Battery, Pneumatic), by Product (Drill, Saw, Stapler, Reamer, ... (Orthopedic, ENT, Oral, Thoracic, Neurology) - Global Forecasts ... Instruments Market is estimated to be worth around ... expected to grow at a moderate CAGR during ...
(Date:11/26/2014)... , Nov. 25, 2014 Nanomix ... on the development of mobile diagnostic tests ... in hospital and pre-hospital settings, today announced ... 13485:2003 certification.  The certification was awarded by ... the world,s leading certification bodies. ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Nanomix Receives ISO 13485:2003 Certification 2
... 4, 2011 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... North America beyond physician offices and outpatient clinics with the ... and reference laboratories. The new line is expected to be ... regulatory approval and other requirements. Roche Diagnostics ...
... CLEMENTE, Calif., Oct. 4, 2011 ReShape Medical®, Inc. ... and chief executive officer.  Interim CEO, Ken Charhut, will ... chairman of the board for ReShape Medical.   ... and CEO of Luminous Medical, Inc., an innovative glucose ...
Cached Medicine Technology:Roche to Expand Coagulation Testing Portfolio, Develop New Systems for Diagnostic Laboratories in US and Canada by 2014 2ReShape Medical Names Richard Thompson President and Chief Executive Officer 2
(Date:11/27/2014)... November 27, 2014 Absolute PhysioCare ... recently announced that its personalized treatment plans, highly ... can help victims of sports injuries reach pre-injury ... or patellofemoral pain syndrome, Absolute Physio has the ... jumper’s knee, ACL tears, meniscal injuries, groin strain ...
(Date:11/27/2014)... November 27, 2014 Cambrionix Ltd today announced ... Fast 50, a ranking of the 50 fastest-growing technology companies ... growth over the last five years. Cambrionix Ltd grew ... ranked first in the region of Cambridgeshire and East and ... Director Says:, “This award is recognition of the hard work ...
(Date:11/27/2014)... An inventor from Buffalo, N.Y., knows ... life, and she wants to lessen its impact. "After ... decided that there needed to be a way to ... to use and producible in design variations, the End ... areas throughout the day. It avoids bad odors, as ...
(Date:11/27/2014)... By Randy Dotinga ... -- Some people,s brains seem pre-wired to acquire a second ... beyond their mother tongue will likely gain a brain boost, ... connected and integrated after learning," said study co-author Ping Li, ... Pennsylvania State University. But it,s even more interesting, Li said, ...
(Date:11/27/2014)... 2014 (HealthDay News) -- Thanksgiving meals can pose a ... diet, an expert says. Many traditional Thanksgiving dishes ... sauce -- are gluten-free, but "when it comes to ... be considered," Dr. Anca Safta, director of the Gluten ... Medical Center in North Carolina, said in a center ...
Breaking Medicine News(10 mins):Health News:Coquitlam Physiotherapy Clinic Now Helps Clients Reach Pre-Injury State 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 3Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 4Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Expert Shares Gluten-Free Thanksgiving Tips 2
... to prescription painkillers are more likely to succeed ... medication buprenorphine-naloxone (Suboxone), report McLean Hospital and Harvard ... the Archives of General Psychiatry. ... for Prescription Opioid Dependence," is the first large-scale ...
... A microsurgical procedure that has lost some ground ... role in the management of selected neurovascular disorders, according ... performs the procedure. "Though its indications are ... make all the difference for certain patients who have ...
... , MONDAY, Nov. 7 (HealthDay News) -- ... school athletes, a new study indicates. In neuromuscular ... progresses to focusing on muscles and motions used in ... and almost 1,500 female basketball and soccer players from ...
... by 2007 annual sales of the cards were at 85,000. America ... in the U.S. over the age of 80 is expected to ... how well they live. The new book, Aging Our Way ... of 30 eldersranging in age from 85 to 102living at home ...
... Go Fish with 3,000 cards. Scientists at Rochester Institute ... game with higher stakes. Instead of cards, they are matching ... body. Their research could lead to drugs that target proteins ... diseases. The three-year study is funded by a $417,000 ...
... who believe a rule or restriction is absolute are more likely ... wiggle room, according to a new study. The findings may ... Arab Spring uprisings, according to the authors of the study to ... Science . In the study, participants read articles that ...
Cached Medicine News:Health News:Suboxone is most effective in treating painkiller addiction 2Health News:University Hospitals Case Medical Center neurosurgeons champion brain bypass in select patients 2Health News:University Hospitals Case Medical Center neurosurgeons champion brain bypass in select patients 3Health News:Specialized Warm-Up May Reduce Girls' Knee Injuries 2Health News:What can we learn from America's fastest growing and least understood age group? 2Health News:Opening the data bank -- scientists try to match new protein structures 2Health News:People Seem More Likely to Follow Rules They Can't Beat 2
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... Thumb Spica Splint provides effective long-term ... custom fit. Adjustable radial and palmar ... for Gamekeper's thumb, de Quervain's, scaphoid ... closure straps.,FormFit™ Splints offer superior fit ...
Qualcare™ Thumb Spica...
... QuickCast® Cast-like splints Slip on, ... and QuickCast conforms to fit. ... Reheat to adjust and reposition. ... with a temperature-sensitive polymer Straps ...
Medicine Products: